Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris

Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris


Meeting to highlight Company's strategy to demonstrate the power of its immunotherapies in combination with immune checkpoint inhibitors , the new standard of care in oncology Scientific presentations to outline Transgene's competitive positioning and its capabilities to engineer the next generation of oncolytic virus based immunotherapies Transgene , a biotech company that designs and develops viral-based immunotherapies, will host today an Immuno-Oncology R&D event for investors and analysts in Paris.



from Biotech News